Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed

Epigenomics. 2023 Nov;15(22):1175-1178. doi: 10.2217/epi-2023-0354. Epub 2023 Nov 15.

Authors

Xiang-Yu Meng^{1

2}, Qiu-Ji Wu³

Affiliations

¹ Health Science Center, Hubei Minzu University, Enshi, 445000, China.
² Hubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi, 445000, China.
³ Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumour Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.

PMID: 37965682
DOI: 10.2217/epi-2023-0354

No abstract available

Keywords: biomarker; molecularly matched therapy; prognosis; targeted therapy; tumor mutation burden.

Publication types

Editorial

MeSH terms

Biomarkers, Tumor* / genetics
Humans
Mutation
Neoplasms* / drug therapy
Neoplasms* / genetics
Prognosis

Substances

Biomarkers, Tumor